

ASX Announcement

Dr Rosalind Wilson appointed to AdAlta Board as Non-Executive Director

MELBOURNE Australia, 1st August 2019, AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body therapeutic, AD-214, toward human clinical trials for Idiopathic Pulmonary Fibrosis, is pleased to announce it has appointed Dr. Rosalind (Ros) Wilson to the role of Non-Executive Director.

Dr Wilson brings to the AdAlta Board more than 20 years' experience from a number of senior leadership and advisory roles across leading international pharmaceutical companies and smaller biotechs. Dr Wilson is clinically trained with extensive experience in devising and implementing clinical research strategy, product life-cycle management and business development. Dr Wilson's clinical expertise will be invaluable as AdAlta prepares to enter into its phase 1 clinical studies in early 2020.

Dr Wilson has held strategy and portfolio management roles at global pharmaceutical company F. Hoffmann - La Roche (Roche), including as global team leader for pertuzumab, a targeted monoclonal antibody developed for breast cancer, and the global team leader for a leading metabolic medicine.

Ros was most recently the Chief Executive Officer at ASX-listed Factor Therapeutics (ASX: FTT), a biomedical technology company developing therapeutics for advanced wound care. Earlier roles included Research Program Officer for lung cancer at Lung Foundation Australia, the leading charity and peak national body for lung disease.

Dr Wilson holds a Bachelor of Medicine, Bachelor of Surgery (MBBS) with first class honours from Monash University and a Master of Business Administration (MBA) with distinction from the London Business School.

"We are thrilled to have someone of Ros' calibre join the AdAlta Board. Her expertise in clinical drug development and commercialisation, particularly in the global pharmaceutical space and her experience in lung disease garnered at Lung Foundation Australia will be of significant benefit as we progress development of our lead fibrosis candidate, AD-214," AdAlta Chairman Paul McLeman said.

Dr Wilson added: "I'm excited to be joining AdAlta at this crucial time. Not only are new therapies for IPF desperately needed, but the commercial landscape is extremely promising, with transactions occurring very early in the clinical development pathway. I look forward to contributing to the company's efforts as it nears the critical milestone of phase I human trials for AD-214, and assisting in bringing this drug and AdAlta's other unique therapies to market."

-ENDS-

Notes to Editors

About AdAlta

AdAlta Limited is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat disease.

I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treating a wide range of human diseases. They are identified and developed using our proprietary technology platform.

We have pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases.

AdAlta is developing its lead i-body candidate, AD-214, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need.

The Company also plans to continue further drug discovery and development directed towards other drug targets and diseases with its i-body technology platform.

Further information can be found at: www.adalta.com.au.

For more information, please contact:

AdAlta Limited

Sam Cobb, CEO

Tel: +61 (0)3 9479 5159

E: s.cobb@adalta.com.au

W: www.adalta.com.au